Navigation Links
Schering-Plough Reports Financial Results for 2009 First Quarter
Date:4/21/2009

reatment of chronic hepatitis C patients 3 years of age and older with compensated liver disease who have failed prior therapy. (Announced March 11)
  • Reported on a Phase II study published in The Lancet of the company's novel oral thrombin receptor antagonist (TRA), which showed no increase in TIMI major and minor bleeding and was well tolerated when given with standard platelet therapy. (Announced March 12)
  • Initiated the first-in-human clinical development program for a new intranasal Live Attenuated Influenza Vaccine for annual seasonal use by Nobilon, Schering-Plough's human vaccine business unit. (Announced March 13)
  • Named a 2009 ENERGY STAR Partner of the Year by the U.S. Environmental Protection Agency for outstanding energy management and reductions in greenhouse gas emissions. (Announced March 30)
  • Reported on a study showing that early use of an investigational dose of INTEGRILIN in patients with Acute Coronary Syndrome was not superior to delayed provisional use. (Announced March 30)
  • Reported on the Dieter Luetticken Award 2008 for alternatives in animal testing, sponsored by Intervet/Schering-Plough Animal Health. (Announced April 7)
  • Gained approval in Canada for SIMPONI, the first once-monthly, subcutaneous therapy for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, marking the first approval in the world for this innovative new product. (Announced April 13)

  • First Quarter 2009 Conference Call and Webcast

    Schering-Plough will conduct a conference call today at 7:30 a.m. (EDT) to review the 2009 first quarter results. To listen live to the call, dial 1-877-565-9664 or 1-706-634-5003 and enter conference ID # 87621385. A replay of the call will be available beginning later on April 21 through 5 p.m. on April 28. To listen to the replay, dial 1-800-642-1687 o
    '/>"/>

    SOURCE Schering-Plough Corporation
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

    Related medicine news :

    1. EPA Names Schering-Plough 2009 EPA ENERGY STAR(R) Partner of the Year
    2. Settlement Hearing on Schering-Plough Corporation Securities Litigation to be Held on June 1, 2009 at 2:00 P.M.
    3. Schering-Plough Withdraws From Barclays Capital Global Healthcare Conference
    4. Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
    5. Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
    6. Schering-Plough Selects Benefit Advocates for Health Advocacy
    7. Schering-Plough Schedules Conference Call and Webcast for 2008 Fourth Quarter and Full Year Earnings
    8. Schering-Plough Announces European Submission of Fertility Medicine Corifollitropin Alfa
    9. Lupin Announces Litigation Settlement with Schering-Plough Corporation for Desloratadine(R)
    10. Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C
    11. Schering-Plough to Webcast R&D Update Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... 28, 2014 (HealthDay News) -- Elementary school students seem to ... them, according to a new study of school officials. ... of Agriculture -- went into effect in the fall of ... stop buying lunch, or throw away most of their food. ... that this isn,t the case. , , "The updated meals ...
    (Date:7/28/2014)... New York, NY (PRWEB) July 28, 2014 ... ) filed on behalf of individuals who were ... Hip Replacement System continue to move forward in U.S. ... reports. According to an Order issued on July 18, ... of a motion filed by the Plaintiffs’ Steering Committee ...
    (Date:7/28/2014)... Braintree, Massachusetts (PRWEB) July 28, 2014 ... the Summit Provider Exchange technology solution ... office integration efforts and support collaboration with their ... 242 bed acute-care medical center located in New ... 800,000 seasonal visitors with a variety of inpatient ...
    (Date:7/28/2014)... chronic medical conditions people have at retirement age, the ... claims. Since nearly four in five older ... Bloomberg School of Public Health in Baltimore said the ... are slowing in the United States. "Living with ... heart failure is now the norm and not the ...
    (Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, 2014 (HealthDay ... are more likely to get a pacemaker than people without ... of more than 16,000 people found that those with dementia ... pacemaker than those without the memory-robbing condition. What ... are so much more likely to be treated with a ...
    Breaking Medicine News(10 mins):Health News:Healthy School Lunches Get Thumbs Up From Students 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3
    ... PHILADELPHIA - Despite recent concerns that medications for attention ... cardiovascular events in children and adolescents, an observational study ... of Medicine and HealthCore Inc. finds they are no ... than those who do not take the drugs. The ...
    ... treated with hormone therapy to suppress tumor growth, obese ... worsening, researchers at Duke University Medical Center have found. ... annual meeting Sunday (May 15, 2011), advances the link ... interest in recent years as the incidence of both ...
    ... simple, minimally-invasive technique using cells from the interior of the ... and most treatable stages, according to a study ... presented at the ATS 2011 International Conference. "Our data ... in the interior surface of the nose may serve as ...
    ... May 13 (HealthDay News) -- A program to boost heart health ... that it,s being expanded to about 20 middle schools in the ... getting the students to: Eat more fruits and ... Get at least 150 minutes of physical activity a week , ...
    ... , FRIDAY, May 13 (HealthDay News) -- Teenagers ... their computers for activities not related to their schoolwork, a ... in New York City found that visiting social networking sites ... linked to drinking. The study, published in the May ...
    ... , THURSDAY, May 12 (HealthDay News) -- People with ... partners by more than 90 percent if they start ... still relatively healthy, researchers announced Thursday. The study, ... was supposed to last until 2015, but the results ...
    Cached Medicine News:Health News:No increase in severe cardiovascular events for children, adolescents taking ADHD medications 2Health News:Obesity linked to higher risk of prostate cancer progression 2Health News:Gene expression changes in nasal cells may help identify lung cancer in earliest stages 2Health News:Gene expression changes in nasal cells may help identify lung cancer in earliest stages 3Health News:Teaching Kids to Make Healthier Choices May Pay Off 2Health News:Teens Who Drink Seem Drawn to Social Networking Sites 2Health News:Early HIV Drug Therapy Protects Sex Partners From Virus 2Health News:Early HIV Drug Therapy Protects Sex Partners From Virus 3
    (Date:7/28/2014)... 2014  TNI BioTech, Inc. (OTCQB: TNIB) ("TNIB" ... the development, marketing and distribution of opioid-related immunotherapies, ... materials with the Securities and Exchange Commission in ... to be held on Thursday, September 4, 2014, ... date for determining those shareholders eligible to receive ...
    (Date:7/28/2014)... 2014 ResMed (NYSE: RMD ), ... cura dei disturbi respiratori del sonno (SDB) e altre ... in Germania contro il produttore Taiwanese di dispositivi medicali, ... apparecchiature da indossare in testa, che violano i brevetti, ... La sentenza della Corte Regionale Distrettuale di ...
    (Date:7/28/2014)... , July 28, 2014  ResMed (NYSE: ... products for the treatment of sleep-disordered breathing and other ... Germany against Taiwanese medical device ... headgear used on APEX WiZARD 210 and 220 masks.  ... in Munich , is appealable, and ...
    Breaking Medicine Technology:TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2
    ... Dec. 30, 2011 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services ... CCM ), operator of the largest ... China, comments on the newly issued Foreign Investment ... healthcare service sectors to "permitted" from "restricted" category. ...
    ... BioDelivery Sciences International, Inc. (Nasdaq: BDSI ) ... Food and Drug Administration (FDA) that a Risk Evaluation ... been approved.  The program, which will be referred to ... Program, was designed to ensure informed risk-benefit decisions before ...
    Cached Medicine Technology:Healthcare Services No Longer "Restricted" in China's Foreign Investment Catalogue 2Healthcare Services No Longer "Restricted" in China's Foreign Investment Catalogue 3ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products 2ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products 3ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products 4
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: